Nanocarrier‐Mediated RNA Delivery Platform as a Frontier Strategy for Hepatic Disease Treatment: Challenges and Opportunities DOI Open Access
Jinhui Fan,

Zhicheng Xiao,

Yafen Dong

и другие.

Advanced Healthcare Materials, Год журнала: 2024, Номер 14(4)

Опубликована: Дек. 26, 2024

Hepatic diseases cause serious public health problems worldwide, and there is an urgent need to develop effective therapeutic agents. In recent years, significant progress made in RNA therapy, molecules, such as mRNAs, siRNAs, miRNAs, aptamers, are shown provide advantages the treatment of hepatic diseases. However, drawbacks RNAs, their poor biological stability, easy degradation by nucleases vivo, low bioavailability, concentrations target tissues, significantly limit clinical application RNA-based drugs. Therefore, exploring developing nanoscale delivery platforms for therapeutics immense value. This review focuses on different types therapeutics, summarizing various strengths weaknesses. Finally, current status future prospects systems therapy discussed.

Язык: Английский

Emerging Mechanisms and Biomarkers Associated with T-Cells and B-Cells in Autoimmune Disorders DOI
Azhagu Madhavan Sivalingam

Clinical Reviews in Allergy & Immunology, Год журнала: 2025, Номер 68(1)

Опубликована: Фев. 11, 2025

Язык: Английский

Процитировано

0
Nanocarrier‐Mediated RNA Delivery Platform as a Frontier Strategy for Hepatic Disease Treatment: Challenges and Opportunities DOI Open Access
Jinhui Fan,

Zhicheng Xiao,

Yafen Dong

и другие.

Advanced Healthcare Materials, Год журнала: 2024, Номер 14(4)

Опубликована: Дек. 26, 2024

Hepatic diseases cause serious public health problems worldwide, and there is an urgent need to develop effective therapeutic agents. In recent years, significant progress made in RNA therapy, molecules, such as mRNAs, siRNAs, miRNAs, aptamers, are shown provide advantages the treatment of hepatic diseases. However, drawbacks RNAs, their poor biological stability, easy degradation by nucleases vivo, low bioavailability, concentrations target tissues, significantly limit clinical application RNA-based drugs. Therefore, exploring developing nanoscale delivery platforms for therapeutics immense value. This review focuses on different types therapeutics, summarizing various strengths weaknesses. Finally, current status future prospects systems therapy discussed.

Язык: Английский

Процитировано

0